Reported Sunday, Lilly Brings Updated Phase 3 Selpercatinib Data Versus Cabozantinib Or Vandetanib In RET-Mutant Medullary Thyroid Cancer To ESMO 2026, Alongside Sofetabart Mipitecan, Olomorasib And Abemaciclib Presentations — 最新ニュース